Asia-Pacific Breast Cancer Therapeutics Market to 2024 - Key Players involved in the research Such As Novartis, Pfizer, R-Pharm, Johnson & Johnson, Eli Lily and AstraZeneca

Researchmoz added Most up-to-date research on "Asia-Pacific Breast Cancer Therapeutics Market to 2024 - Key Players involved in the research Such As Novartis, Pfizer, R-Pharm, Johnson & Johnson, Eli Lily and AstraZeneca" to its huge collection of research reports.

Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages of the disease, the survival rate rapidly decreases. HER2-positive breast cancer is an aggressive disease, and historically has had a worse overall survival (OS) than HER2-negative disease, which is considered less aggressive.

The current marketed drug landscape in breast cancer includes a mix of targeted therapies, chemotherapies, and hormonal agents. Metastatic breast cancer is not considered a curable disease, and in the course of therapy patients can receive up to three lines of endocrine agents and four or more lines of chemotherapy, as well as targeted therapies for earlier lines of therapy - often in no particular sequence.

Hormone therapy is the mainstay of treatment for patients with HR-positive disease, but triple-negative breast cancer (TNBC) patients who lack HR expression are normally treated with generic chemotherapies. This is because there are no approved targeted therapies currently available in the TNBC setting. The HER2-positive breast cancer market is dominated by the HER2-targeting mAb Herceptin, the most established drug in this disease area.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1811473

Herceptin is used in nearly all settings of HER2-positive breast cancer and in all markets accessed in this report, as it was demonstrated to significantly improve the OS of women with this disease type. The current breast cancer pipeline is demonstrative of strong innovation in cancer overall, and a significant number of new drug launches are expected during the forecast period.

This is likely to have a significant impact on the competitive landscape, particularly in the early lines of metastatic disease. The emergence of novel biomarkers will also impact treatment decisions for TNBC patients, and will provide new options for targeted therapy in this patient population, fulfilling a long-standing unmet need. One of the key drivers of the breast cancer therapeutics market in the APAC region is the increase in patient volume.

It is also expected to be driven by the anticipated approval of promising therapies within several distinct patient segments, as well as the growing market uptake of already approved therapies in the APAC markets.

Although several branded drugs are expected to go off patent during the forecast period, the impact of this on the market will be offset by the launch of upcoming therapies such as Verzenio, Lynparza, Nerlynx, talazoparib, alpelisib, taselisib, Keytruda, Tecentriq, margetuximab and ipatasertib, and the increasing uptake of already approved therapy such as Ibrance, Kadcyla, Perjeta and Kisqali.

Browse TOC @ https://www.researchmoz.us/breast-cancer-therapeutics-in-asiapacific-markets-to-2024-growth-driven-by-increasing-uptake-of-targeted-therapies-and-rising-prevalence-report.html/toc

Scope

• The breast cancer Asia-Pacific market will be valued at $4.75 billion in 2024, growing from $2.16 billion in 2017 at a compound annual growth rate (CAGR) of 11.9%.
• How will immune checkpoint inhibitors such as Keytruda and Tecentriq, PARP inhibitors such as Lynparza and talazoparib, and PI3K inhibitors such as taselisib and alpelisib contribute to growth?
• What effect will the patent expirations of branded therapies have on market value?
• The breast cancer pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as the lack of targeted therapies available for TNBC patients?
• What implications will the increased focus on targeted therapies have on the future of breast cancer treatment?
• Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
• How have the late-stage therapies performed in clinical trials?
• How would the approval of Keytruda, Tecentriq, Lynparza, talazoparib and ipatasertib to treat TNBC patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
• The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
• How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
•  How could changes in risk factors such as population age, early menstruation, late menopause, obesity, smoking, lack of breast-feeding and alcohol consumption influence the market?
• Licensing deals are the most common form of strategic alliance in breast cancer, with total deal values ranging from under $10m to over $1 billion.
• How do deal frequency and value compare between target families and molecule types?
• What were the terms and conditions of key licensing deals?

Reasons to buy

This report will enable you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the breast cancer market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
• Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict breast cancer market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Southeast Asia Breast Cancer Therapeutics Market, 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Researchmoz added Most up-to-date research on "Southeast Asia Breast Cancer Therapeutics Market, 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market" to its huge collection of research reports.

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1068037

Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.

Browse TOC @ https://www.researchmoz.us/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022-increasing-prevalence-and-usage-of-premium-targeted-therapies-to-drive-the-market-report.html/toc

Scope

The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.

• Which drugs are used as the standard treatment in each setting of the disease?
• What are the competitive advantages of the existing novel drugs?
• Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?

There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.

• Which molecular targets appear most frequently in the pipeline?
• There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
• Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.

• How do failure rates vary by stage of development, molecule type, and molecular target?
• How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.

• Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?

Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.

• How will the annual cost of therapy and market size vary between the eight Southeast Asian markets? 
• What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
• How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
• How will the potential launch of biosimilars influence each country? 
• Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Various drivers and barriers will influence the market over the forecast period.

• What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
• What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
• Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth. 
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Southeast Asia Breast Cancer Therapeutics Market, 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Researchmoz added Most up-to-date research on "Southeast Asia Breast Cancer Therapeutics Market, 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market" to its huge collection of research reports.

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.

Scope

The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.

• Which drugs are used as the standard treatment in each setting of the disease?
• What are the competitive advantages of the existing novel drugs?
• Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1068037

There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.

• Which molecular targets appear most frequently in the pipeline?
• There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
• Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.

• How do failure rates vary by stage of development, molecule type, and molecular target?
• How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.

• Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?

Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.

• How will the annual cost of therapy and market size vary between the eight Southeast Asian markets? 
• What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
• How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
• How will the potential launch of biosimilars influence each country? 
• Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Various drivers and barriers will influence the market over the forecast period.

• What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
• What factors are most likely to drive the market in these countries?

Reasons to buy
This report will allow you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
• Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth. 
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Browse More Details @ https://www.researchmoz.us/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022-increasing-prevalence-and-usage-of-premium-targeted-therapies-to-drive-the-market-report.html